Incidence and types of adverse events during mass vaccination campaign with the meningococcal a conjugate vaccine (MENAFRIVAC™) in Cameroon

Purpose A new vaccine against meningitis A was introduced in Africa meningitis belt in 2010. This study was planned to describe the incidence and types of adverse events following immunization (AEFIs) with a new conjugate vaccine against meningitis A (MenAfrivac™) in a Cameroonian vaccination campai...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacoepidemiology and drug safety 2016-10, Vol.25 (10), p.1170-1178
Main Authors: Ateudjieu, Jerome, Stoll, Beat, Nguefack-Tsague, Georges, Yakum, Martin Ndinakie, Mengouo, Marcellin Nimpa, Genton, Blaise
Format: Article
Language:English
Subjects:
Adolescent
Adult
Adverse Drug Reaction Reporting Systems
AEFI incidence
Age Distribution
Cameroon
Child
Child, Preschool
Female
Fever - chemically induced
Fever - epidemiology
Gastrointestinal Diseases - chemically induced
Gastrointestinal Diseases - epidemiology
Humans
Incidence
Infant
Male
Mass Vaccination
MENAFRIVAC
meningitis A
Meningitis, Meningococcal - prevention & control
Meningococcal Vaccines - administration & dosage
Meningococcal Vaccines - adverse effects
Neisseria meningitidis
pharmacoepidemiology
vaccination campaign
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose A new vaccine against meningitis A was introduced in Africa meningitis belt in 2010. This study was planned to describe the incidence and types of adverse events following immunization (AEFIs) with a new conjugate vaccine against meningitis A (MenAfrivac™) in a Cameroonian vaccination campaign. Methods The campaign was conducted in Adamawa and North West regions in December 2012 and the AEFIs enhanced surveillance from December 2012 to January 2013. Incidence rates (IR) of overall and serious AEFIs were estimated as well as AEFI incidence rates by type, age group and region. AEFI symptoms were aggregated in System Organ Class (SOC). Results Of 2 093 381 persons vaccinated, 1352 AEFIs were reported. Of these, 228 (16.9%) were excluded because of not meeting inclusion criteria and 1124 (83.1%) included (IR: 53.7/100 000 doses administered/8 weeks). Of the 82 serious AEFIs reported, 52 (63.2%) met the case definition. 23 (28.1%) were investigated, of which 4 (17.4%) were probably vaccine product‐related reactions (IR: 0.2/100 000 doses administered/8 weeks). Fever was the most common reported AEFI with 626 cases (IR: 31.4/100 000 doses administered/8 weeks). The proportion of people with the SOC “Gastrointestinal disorders” was significantly lower in ages 5–15 and 16–29 years than 1–4 years [aRR = 0.63(0.42–0.93) and 0.54(0.36–0.81) respectively]. Conclusion Incidence and types of AEFI reported during MenAfriVacTM vaccination campaign organized in Cameroon in 2012 did not suggest concern regarding the vaccine safety. Differences in frequency of AEFIs types per age group could guide the monitoring of AEFIs frequency in future campaigns. Efforts are needed to improve the investigation rate of serious AEFIs. Copyright © 2016 John Wiley & Sons, Ltd.
ISSN:1053-8569
1099-1557
DOI:10.1002/pds.4027